ERBB2 and breast cancer: Indeed, different prognostic values have been described among BC subtypes, with higher levels being associated with a good outcome in TNBC patients with residual disease after NAC,39 but with a poor outcome in HER2-positive patients.23 Asano et al.40 suggested that RCB combined with post-NAC TILs could be a more sensitive predictor for BC recurrence after NAC, with a 0.048 risk of recurrence (hazard ratio) in global population for RCB-TILs-positive patients (p < 0.001), 0.041 in TNBC patients (p = 0.018), 0.134 in HER2-positive patients (p = 0.036) and 0.081 for luminal tumours (p = 0.002).